Entero Therapeutics, Inc. Quarterly Debt-to-equity in % from Q2 2017 to Q3 2024

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Entero Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q2 2017 to Q3 2024.
Entero Therapeutics, Inc. Debt-to-equity for the quarter ending September 30, 2024 was 128 %, a 6.19% increase year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Growth (%)

Period	Value	YoY Chg	Change %	Date
Q3 2024	128	+7.48	+6.19%	Sep 30, 2024
Q2 2024	108	-284	-72.5%	Jun 30, 2024
Q1 2024	94.6	+372		Mar 31, 2024
Q4 2023	116	+316		Dec 31, 2023
Q3 2023	121	+308		Sep 30, 2023
Q2 2023	392	+588		Jun 30, 2023
Q1 2023	-277	+98	+26.1%	Mar 31, 2023
Q4 2022	-199	-942	-127%	Dec 31, 2022
Q3 2022	-187	-570	-149%	Sep 30, 2022
Q2 2022	-197	-284	-326%	Jun 30, 2022
Q1 2022	-375	-493	-419%	Mar 31, 2022
Q4 2021	742	+515	+227%	Dec 31, 2021
Q3 2021	383	+288	+306%	Sep 30, 2021
Q2 2021	86.9	-145	-62.5%	Jun 30, 2021
Q1 2021	118	-44	-27.2%	Mar 31, 2021
Q4 2020	227	+53.2	+30.6%	Dec 31, 2020
Q3 2020	94.4	-71.6	-43.2%	Sep 30, 2020
Q2 2020	232	+111	+91.6%	Jun 30, 2020
Q1 2020	162	+81.1	+101%	Mar 31, 2020
Q4 2019	174	+97.4	+128%	Dec 31, 2019
Q3 2019	166	+71	+74.7%	Sep 30, 2019
Q2 2019	121	-1.34	-1.1%	Jun 30, 2019
Q1 2019	80.6	-77.6	-49.1%	Mar 31, 2019
Q4 2018	76.4	-74.4	-49.3%	Dec 31, 2018
Q3 2018	95	-34.1	-26.4%	Sep 30, 2018
Q2 2018	122	+1.1K		Jun 30, 2018
Q1 2018	158			Mar 31, 2018
Q4 2017	151			Dec 31, 2017
Q3 2017	129			Sep 30, 2017
Q2 2017	-973			Jun 30, 2017

* An asterisk sign (*) next to the value indicates that the value is likely invalid.